Division of Gynecologic Oncology, Department of Obstetrics and Gynecology (Drs. Renz, Diver, English, Dorigo, and Karam).
Department of Radiation Oncology (Dr. Kidd), Stanford University School of Medicine, Stanford, California.
J Minim Invasive Gynecol. 2020 Feb;27(2):482-488. doi: 10.1016/j.jmig.2019.04.006. Epub 2019 Apr 10.
To evaluate practice patterns among gynecologic oncologists with regard to sentinel lymph node injection and biopsy in endometrial cancer.
An observational study with no control group.
Active members of the Society of Gynecologic Oncology.
After institutional review board approval, we performed an online survey among active members of the Society of Gynecologic Oncology. Members were contacted via e-mail and their answers anonymously captured. Study data were collected using REDCap (REDCap developed by Vanderbilt University, Nashville TN).
Three hundred eighteen of 1216 listed members completed the online survey. The majority of respondents (82.7%) perform sentinel lymph node sampling for endometrial cancer staging. Most technical aspects of sentinel lymph node sampling were consistently applied by the vast majority of respondents, including the choice of indocyanine green as a lymphatic tracer (97.3%) and its injection into the cervix (100%). Other technical aspects of sentinel lymph node sampling, such as the depth of injection, varied among respondents. Although 50.9% of the respondents perform an intraoperative assessment of the uterus by frozen section, only 17.9% assess sentinel lymph nodes by frozen section and/or touch prep. Some of the respondents' approaches are based on limited data, including (1) the use of sentinel lymph node injection and biopsy for high-risk histologies (performed by 69%-75% of the respondents dependent on the histology), (2) omitting side-specific completion lymphadenectomy in the absence of sentinel node mapping (in up to 57.8%), or (3) when lymph node metastases are present (in 39.9%).
In summary, despite the growing use of sentinel lymph node injection and biopsy in endometrial cancer, practice patterns vary considerably among providers sampled by this survey. Some of the decisions are based on limited evidence and, in some instances, deviate from current published guidelines.
评估妇科肿瘤学家在子宫内膜癌中进行前哨淋巴结注射和活检的实践模式。
无对照组的观察性研究。
妇科肿瘤学会的活跃成员。
在机构审查委员会批准后,我们对妇科肿瘤学会的活跃成员进行了在线调查。通过电子邮件联系成员,并匿名记录他们的答案。使用 REDCap(由田纳西州纳什维尔的范德比尔特大学开发的 REDCap)收集研究数据。
在列出的 1216 名成员中,有 318 名完成了在线调查。大多数受访者(82.7%)为子宫内膜癌分期进行前哨淋巴结采样。绝大多数受访者一致应用了前哨淋巴结采样的大多数技术方面,包括选择吲哚菁绿作为淋巴示踪剂(97.3%)和将其注射到宫颈(100%)。前哨淋巴结采样的其他技术方面,如注射深度,在受访者中有所不同。尽管 50.9%的受访者通过冷冻切片对子宫进行术中评估,但只有 17.9%的受访者通过冷冻切片和/或触摸准备评估前哨淋巴结。一些受访者的方法基于有限的数据,包括(1)在前哨淋巴结注射和活检用于高危组织学的情况下使用(根据组织学,69%-75%的受访者使用),(2)在没有前哨淋巴结映射的情况下省略侧特异性完成淋巴结切除术(最高可达 57.8%),或(3)在存在淋巴结转移的情况下(39.9%)。
总之,尽管在子宫内膜癌中越来越多地使用前哨淋巴结注射和活检,但本调查抽样的提供者之间的实践模式差异很大。一些决策基于有限的证据,在某些情况下,偏离了当前的出版指南。